HCV-related hepato cellular carcinoma
Conditions
Interventions
Adjuvant interferon alpha therapy. Three times of 3,000,000 units / a week.
Close follow-up
Sponsors
Tokyo University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Ages between 61 and 77 years old 2) Primary HCC or recurrent HCC more than two years after previous therapy 3) Classical HCC 4) HCV chronic hepatitis or cirrhosis 5) No extrahepatic lesions 6) Fine or moderate organ function fulfilling the following criteria. 7) Child-Pugh score < 8 8) ECOG performance status 0-2 9) CES-D score <16 10) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Positive HBs-Ag 2) Other anticancer treatment or interferon therapy within 3 months before surgery. 3) Specific drug which is forbidden in this trial is needed. 4) Participating in other clinical trial regarding HCC 5) Autoimmune hepatitis, alcoholic hepatitis, etc. 6) Allergy for specific biologics 7) Severe postoperative complications 8) Asthma 9) Diabetes requiring insulin therapy 10) Severe hypertension 11) Heart disease that complicates perioperative treatments 12) Interstitial pneumonia 13) Psychiatric disorder 14) Malignant disease in other organ within 5 years 15) Moderate or severe renal dysfunction (estimated Ccr < 30ml/min) 16) Other reason that an attending doctor considers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurence free survival | — |
Countries
Japan
Contacts
Public ContactTakeaki Ishizawa
Tokyo University Hospital Hepato-Biliary-Pancreatic Surgery Division
Outcome results
None listed